Eli Lilly and Company
) and Kowa Pharmaceuticals America, Inc. recently presented
positive results on their cholesterol management drug, Livalo
(pitavastatin) 4 mg, from a phase IV study.
The 12-week, randomized, double-blind, double-dummy,
active-controlled, parallel-group, superiority study was
conducted to evaluate the efficacy of Livalo compared to that of
) Pravachol (pravastatin) 40 mg for the reduction of
low-density lipoprotein cholesterol (LDL-C) in HIV-infected
adults with high cholesterol (dyslipidemia).
Results showed that patients receiving Livalo experienced a
significantly higher LDL-C reduction compared to patients on
Pravachol (31% reduction vs 21% reduction). Meanwhile, the
occurrence of treatment emergent adverse events was lower in the
Livalo arm compared to Pravachol (61.1% vs 62.7%).
Eli Lilly and Kowa intend to analyze the results further.
Livalo is currently approved for the treatment of high
cholesterol. It has been available in the US since Jun 2010 and
is approved in several other countries including Japan.
Eli Lilly currently carries a Zacks Rank #2 (Buy). The biggest
near-term challenge for Eli Lilly will be to replace the revenues
that will be lost to generic competition now that Zyprexa has
lost US and EU exclusivity. The generic threat will continue to
pose challenges for Eli Lilly with Cymbalta slated to lose patent
protection in late 2013 and Evista in 2014. On the flip side, the
Animal Health business and the diabetes franchise should provide
some downside support. We are also pleased to see Eli Lilly
pursuing small acquisitions and in-licensing deals to boost its
Other large-cap companies like
) also carry a Zacks Rank #2.
Avanir Pharmaceuticals, Inc.
) also looks attractive with a Zacks Rank #2.
AVANIR PHARM (AVNR): Free Stock Analysis
BRISTOL-MYERS (BMY): Free Stock Analysis
LILLY ELI & CO (LLY): Free Stock Analysis
NOVO-NORDISK AS (NVO): Free Stock Analysis
To read this article on Zacks.com click here.